![]() Since 2018, Scribe therapeutics has been at work on their solution. The outcomes are that Scribe has already raised 20 million dollars in a Series A funding round (with some amount of prior seed funding granted) led by Andreessen Horowitz. Both of them saw a very interesting opportunity to utilize the sort of technology development that Ben had been doing, which he was extremely crazy about proceeding, as well as to concentrate it on this challenge of neurodegenerative disease. ![]() Meantime, Staahl was studying the treatments for disorders that particularly bring about neural degeneration – something that had not earlier been part of Doudna’s laboratory’s study before.ĭoudna said that he had a significant period in the laboratory, establishing methods for neurons, and attempting to bring that technology to a point where it could be expanded as a genuine therapy for the neurodegenerative disease, with Huntington’s as a model. The groundbreaking research article by Doudna on CRISPR was published in 2012, and Oakes instantly saw the potential, so he joined her laboratory. This drove him to start a study in ZFN (Zinc-Finger Nuclease)- based genome editing – a precursor method to CRISPR that was time-consuming, far less particular, and far more work-intensive. S how they can best solve those underlying issues of Huntington’s disease. Oakes described that he set out on this trip to comprehend how they could, as well a Oakes was set out to be a practicing medical doctor, but he turned back to his research to study the underlying reasons for disease. How gene editing, and CRISPR specifically, could be used to assist in the treatment of Huntington’s disease was Staahl’s interest in research. Benjamin Oakes and Staahl worked together at Doudna’s laboratory, where Oakes was a student and Staahl was a Postdoctoral researcher. However, it is primarily led by Benjamin Oakes, CEO, and founder, and Brett T. Jennifer Doudna ( The Nobel Prize Winner in Chemistry 2020 ) is part of the leadership team behind Scribe Therapeutics. Scribe Therapeutics established by 2 ex-members of CRISPR pioneer Jennifer Doudna’s UC Berkeley genetics lab (with Doudna herself) unveiled a platform made especially to assist develop and engineer new therapeutics based on CRISPR for resolving particular diseases, with permanent treatments in people. To learn more about Scribe’s mission to rewrite the story of disease, visit View source version on businesswire.A platform for engineering CRISPR-based medicines by Scribe Therapeutics The company is backed by leading individual and institutional investors including Andreessen Horowitz. Founded by CRISPR inventors and leading molecular engineers Benjamin Oakes, Brett Staahl, David Savage, and Jennifer Doudna, Scribe is overcoming the limitations of current genome editing technologies by developing custom engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. Scribe Therapeutics is a molecular engineering company focused on building best-in-class in vivo therapies to permanently treat the underlying cause of disease. Scribe is also eligible to receive tiered, high single digit to sub-teen royalties. Scribe will receive $15 million upfront and is eligible for more than $400 million in potential development and commercial milestone payments between the two targets of interest. Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need. “We’re proud to collaborate with Biogen and apply our uniquely customized approaches with the goal of developing new, safe and effective genetic medicines for neurodegenerative disease.” “Scribe has designed, engineered and tested thousands of evolved CRISPR enzymes to build an advanced platform for creating breakthrough in vivo treatments,” said Benjamin Oakes, CEO and co-founder of Scribe Therapeutics. The company’s first technology, X-Editing (XE), provides greater editing activity, specificity and deliverability than other CRISPR genome editing tools currently available. Scribe’s platform is focused on engineering, delivering, and developing novel, custom CRISPR molecules. (Nasdaq:BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS). Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. Committed to expanding treatment for underserved genetic conditions, Scribe and Biogen to collaborate on the development of novel genetic medicines for neurodegeneration
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |